Anti-Rel B (phospho-S552) Antibody |产品详情|进口试剂采购网

您好，欢迎来到拜力生物网站！请登录注册

我的订单 | 联系我们 | 在线客服QQ：3012681483 | 客服电话：400-968-7988 | 工作时间：08:30-17:30

主营产品： ELISA试剂盒、抗体、补体血清、兔补体、干扰素、小鼠测温仪、进口试剂、Quidel代理、Swant代理、PBL Assay Science代理

网站首页产品中心代理品牌新闻资讯资源中心关于我们

所在位置：首页 > 产品中心 > Antibodies > Antibodies产品

订购信息

上海拜力生物科技公司

Tel:400-968-7988 021-33779008

Anti-Rel B (phospho-S552) Antibody

品牌：Antibodies

货号：

规格：50µl

货期：

应用：

咨询客服

立即购买加入购物车

Anti-Rel B (phospho-S552) Antibody

商品详情参考文献相关资料

Overview

Name:	Anti-Rel B (phospho-S552) Antibody See all Rel B primary antibodies
Description:	Rabbit polyclonal antibody to Rel B (phospho-S552)
Specificity:	p-Rel B (S552) pAb detects endogenous levels of Rel B protein only when phosphorylated at Ser552.
Applications:	WB, IHC
Reactivity:	Human, Mouse, Rat
Immunogen:	Synthetic phosphopeptide derived from human Rel B around the phosphorylation site of Serine 552.
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	Unconjugated
Molecular Weight:	~ 70 kDa
Purity:	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Product Form:	1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.

Target

Function:	NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52.
Post-Translational Modification:	Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.
Cellular Location:	Nucleus. Cytoplasm > Cytoskeleton > Microtubule organizing center > Centrosome. Colocalizes with NEK6 in the centrosome.
Database Links:	Entrez Gene: 5971?Human Entrez Gene: 19698?Mouse Entrez Gene: 100360982?Rat Omim: 604758?Human SwissProt: Q01201?Human SwissProt: Q04863?Mouse Unigene: 654402?Human Unigene: 1741?Mouse
Synonyms:	I REL Antibody I-Rel Antibody IREL Antibody Nuclear factor of kappa light polypeptide gene enhancer in B cells 3 Antibody Rel B Antibody relB Antibody RELB_HUMAN Antibody Reticuloendotheliosis viral oncogene homolog B Antibody Transcription factor Rel B Antibody Transcription factor RelB Antibody v rel avian reticuloendotheliosis viral oncogene homolog B Antibody v rel reticuloendotheliosis viral oncogene homolog B Antibody
Information:	Target information shown above is from the UniProt Consortium.